An update from Abbisko Cayman Limited ( (HK:2256) ) is now available.
Abbisko Cayman Limited has announced the composition of its board of directors and the roles of its members. The board includes both executive and independent non-executive directors, with Dr. XU Yao-Chang serving as the Chairman. The company has also established three committees: Audit, Remuneration, and Nomination, each with designated members and chairpersons. This organizational structure aims to enhance corporate governance and strategic decision-making, potentially impacting the company’s operational efficiency and stakeholder confidence.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands, operating within the pharmaceutical or biotechnology industry. It is listed under the stock code 2256, focusing on innovative drug development and related services.
YTD Price Performance: 31.09%
Average Trading Volume: 2,827,122
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$4.1B
For an in-depth examination of 2256 stock, go to TipRanks’ Stock Analysis page.